Source: International Business Times
The United States is a key market for the pharmaceutical industry, and AstraZeneca had already planning to invest $3. 5 billion there by the end of 2026 AFP British pharmaceutical giant AstraZeneca announced Tuesday that it has begun moving some of its European production to the United States, ahead of President Donald Trump's possible tariffs on the sector. "Our company is firmly committed to investing and growing in the US," chief executive Pascal Soriot said in an earnings statement, which also reported that first-quarter profit rose by over 30 percent to $2.
Aller á la Source
Nouvelles connexes
